Staying informed on the latest in cachexia, sarcopenia, and wasting disorders research is essential yet challenging. The SCWD Digest offers concise updates and expert insights into significant studies and developments. We highlight and link directly to leading research, making it easier for healthcare professionals to access and apply groundbreaking findings. Our goal: empower the medical community to advance patient care worldwide efficiently.
Malnutrition is a common phenomenon, particularly in those at an increased risk of muscle mass and function losses. In this systematic review and meta-analysis, we aimed to explore the association of malnutrition with sarcopenia in middle-aged and older adults and...
Sarcopenia is the age-related loss of skeletal muscle mass and function. Recently, research has focused on defining diagnostic criteria for this condition, now recognized as a muscle disease with a specific identifying code (ICD-10: M62.84). The diagnostic process for sarcopenia...
Non-steroidal anti-inflammatory drugs (NSAIDs) may influence musculoskeletal health. The purpose of this study was to compare the effects of three different NSAIDS: naproxen sodium, ibuprofen, flurbiprofen or a placebo on musculoskeletal adaptations in rodents with or without 6 weeks of aerobic...
Fasting shows promise for public health, but concerns about muscle loss hinder its acceptance, particularly among the elderly. We explored the impact of long-term fasting (12 days, 250 kcal/day) on muscle structure, metabolism and performance. We prospectively assessed muscle volume, composition, relaxometry...
Programmed cell death plays a critical role in skeletal muscle atrophy. Ferroptosis, an iron-dependent form of programmed cell death driven by lipid peroxidation, has been implicated in various diseases, but its role in skeletal muscle atrophy remains unclear. Ferroptosis in...
There is a dearth of screening tools for cardiorespiratory disease and fracture risk, such as risk prediction models, for adults with cerebral palsy (CP). There is heterogeneity of pathophysiology related to the severity of CP and aging, such that a...
Hypothalamic inflammation plays a pivotal role in appetite dysregulation across various pathological conditions, including cancer cachexia. However, delivering anti-inflammatory agents to microglia, key mediators of hypothalamic inflammation, remains challenging due to the unsurmountable blood-brain barrier (BBB). To overcome this challenge,...
Metabolic syndrome (MetS) is a set of five cardiometabolic risk factors that typically worsen with age. One exercise-training programme is effective at improving those factors in middle-aged individuals with MetS. To our knowledge, exercise-training efficacy as MetS individuals age has...
Around 80% of patients with advanced cancer have cancer cachexia (CC), a serious complication for which there are currently no FDA-approved treatments. Nuciferine (NF) is the main active ingredient of lotus leaf, which has anti-inflammatory, anti-tumour and other effects. The...
Visceral obesity (VO), associated with excessive visceral adipose tissue (VAT), has been extensively studied in cancer. However, whether low VAT can predict the prognosis of colorectal liver metastases (CRLM) undergoing neoadjuvant chemotherapy (NAC) remains unknown. This multicentre real-world cohort study...
As society ages, identifying individuals at risk of sarcopenia becomes essential. Several plasma biomarkers are used to assess musculoskeletal status, but their results are inconsistent. Extracellular vesicles (EVs) are investigated as disease biomarkers due to their role in transporting molecules...
Falls constitute a significant public health concern among older adults, particularly those with diminished muscle health integrity. The relative contributions of reduced muscle mass versus impaired muscle function to fall risk remain debated. Discrepant conclusions in previous studies exist due...
Additional tools are needed to assess mortality risk among patients with cancer. Patients with chronic graft vs. host disease (cGVHD) after allogeneic haematopoietic cell transplantation (HCT) represent a high-risk cancer population with mortality risk explained by cGVHD severity, but also...
